The aim of this study is assessment the therapeutic effects of atorvastatin on blood sugar control, decreasing insulin resistance and inflammatory markers in patient with diabetes type two. In this study 88 patients with diabetes type 2 who had Hb A1C less than 9, triglyceride less than 250, low density lipoprotein between 70 to 160, high density lipoprotein more than 35, total cholesterol less than 240 and are treated with oral hypoglycemic agents. Patients are excluded if there were evidence of diabetes complications such as retinopathy, nephropathy and Glomerular Filtration Rate less than 60, cardiovascular involvement such as Congestive Heart Failure,Ischemic Heart Diseases,Acute Myocardial Infarction during recent 1 year, history of epileptic disorders, history of significant active gastrointestinal diseases such as active peptic ulcer disease in recent 1 year, active significant hematologic , hepatic and musculoskeletal diseases. Patients who treated with insulin, got to acute illness, allergic history to statins, history of alcohol and opium consumption, breast feeder mothers and pregnant patients, have consumed statins during recent 6 months were also exculded. Patients divided into case and control group randomly and in case group the patients treated with atorvastatin 40mg per day for 12 weeks in addition to their medications and control group consumed placebo in addition to their medications. At the beginning of study both groups checked for Complete Blood Count,Alanine aminotransferase, Aspartate aminotransferase,Blood Urea Nitrogen,Creatinine,HbA1C, Fasting Blood Sugar,lipid profiles, Creatin phosphokinase, Lactate dehydrogenase, microalbuminurea, insulin, hsCRP, Tumor necrosis factor alpha, adiponektin and leptin and finally at the end of study all tested will be repeated and every changes in these tests will be analized.